Joanna Sadowska: Bayer’s Asundexian Reduces Ischemic Stroke Risk in Phase 3 Trial
Joanna Sadowska, Biopharma Account Specialist, shared on LinkedIn:
”Big News – Bayer’s asundexian reduces ischaemic stroke risk in Phase 3 clinical trial
Bayer has announced positive Phase 3 results from the OCEANIC-STROKE study evaluating asundexian, an investigational once-daily oral Factor XIa inhibitor, for secondary stroke prevention.
This is the first study that successfully completed Phase 3 for Factor XIa.
Approximately 12 million people worldwide experience a stroke each year, with 20-30% being recurrent strokes.
One in five stroke survivors will have another stroke within five years, and these recurrent strokes tend to be more disabling and carry a higher mortality risk than first strokes.
Asundexian is a direct Factor XIa inhibitor designed to reduce thrombus formation that can lead to vessel blockage.
It has a novel mechanism targeting the coagulation pathway differently from current antiplatelet therapies.
Asundexian has received FDA Fast Track Designation for stroke prevention in this patient population.”
Stay informed with Hemostasis Today.
-
Nov 8, 2026, 15:0310 Posts Not to Miss This Week
-
Nov 8, 2026, 14:55Andra T.: Antiphospholipid Syndrome and Its Thrombotic Risks
-
Nov 8, 2026, 14:06Shayan Mohammadmoradi: ZEUS Trial-Inflammation Reduction Without Fewer Cardiovascular Events
-
Nov 8, 2026, 14:05Kausik Ray: Plaque-Guided Care for Better Coronary Outcomes
-
Nov 8, 2026, 14:05Athira Elssa Johnson: Understanding Coronary Thrombosis and Its Risks
-
Nov 8, 2026, 14:04Sanjiv Beri: Blood Type Compatibility and the Balance of Giving and Receiving
-
Nov 8, 2026, 14:02Gabriela Hobbs: Recognizing Outstanding Abstract Achievements-ASH 2026
-
Nov 8, 2026, 12:22Marc Carrier: Advancing Catheter-Related Thrombosis Prevention Through Factor XI Inhibition
-
Nov 8, 2026, 11:56Why Genetic Predisposition Does Not Always Lead to Thrombosis – Stork Genetics